Shanghai Fosun Pharmaceutical To Enter China's Injectable Market
This article was originally published in PharmAsia News
Executive Summary
Shanghai Fosun Pharmaceutical recently revealed that its two wholly-owned subsidiaries, Fosun International and Fosun Industrial, signed an agreement to buy from Beijing Hexin Boye Consultancy and Aleph Biomedical the totaling stake of 75 percent in Aleph Biomedical, allegedly at RMB 660 and 9 million